Home Blog of Signal Transduction Transmembrane Transporters MCT

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

MCT

Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells

119 views | Jan 31 2024

The study identifies that tamoxifen-resistant breast cancer cells depend on enhanced glycolysis, particularly lactate metabolism mediated by MCT1 and LDHB, proposing that targeting these pathways could offer a promising strategy for treating tamoxifen-resistant breast cancer. [Read the Full Post]

Ultra-stable MOF@MOF nanoplatform for photodynamic therapy sensitized by relieved hypoxia due to mitochondrial respiration inhibition

120 views | Jan 16 2024

The innovative MOF@MOF structure, bolstering stability and effectively alleviating hypoxia in tumors via 7ACC2, represents a groundbreaking leap in enhancing photodynamic therapy, heralding a promising era for MOF-based nanomedicines. [Read the Full Post]

Chaperone-mediated autophagy protects against hyperglycemic stress

108 views | Dec 12 2023

The study demonstrates the existence of chaperone-mediated autophagy (CMA) in rainbow trout, revealing its activation under high-glucose conditions, mediated by the KFERQ motif, Lamp2A, mitochondrial reactive oxygen species, and the Nfe2l2/Nrf2 pathway, highlighting its crucial role in protecting against glucose-induced stress. [Read the Full Post]

Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack

101 views | Sep 26 2023

The study revealed that inhibiting MCT4 in hepatocellular carcinoma improved immune responses, suppressed tumor growth, and enhanced the efficacy of immunotherapy, suggesting MCT4 as a potential therapeutic target for tailoring HCC treatment. [Read the Full Post]

Mechanism of action of reserpine in producing gastric haemorrhage and erosion in the mouse

131 views | Sep 26 2023

Reserpine-like drugs, such as reserpine and deserpidine, induce gastric hemorrhage in mice within six hours of subcutaneous injection, likely through a mechanism involving central components and the release of 5-hydroxytryptamine. [Read the Full Post]

HTLV-1 bZIP factor-induced reprogramming of lactate metabolism and epigenetic status promote leukemic cell expansion

261 views | Sep 26 2023

The study demonstrates that the viral oncogene HBZ upregulates TAp73, which in turn promotes lactate excretion through the upregulation of lactate transporters MCT1 and MCT4, revealing a potential common mechanism underlying cancer metabolism and suggesting the therapeutic potential of targeting this pathway. [Read the Full Post]

Effect of Lactate Export Inhibition on Anaplastic Thyroid Cancer Growth and Metabolism

198 views | Jun 17 2022

Bixiao Zhao et al. thought that targeting suppression of glycolytic and lactate processing pathways might represent an effective treatment strategy for ATC. [Read the Full Post]

Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma

278 views | Jul 27 2021

Yuanyuan Guo et al. proposed that MCT1 inhibitor (AZD3965) was useful for suppressing RCC. [Read the Full Post]

In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model

0 views | Aug 07 2020

Xiaowen Guan et al. indicated AZD3965 is a potent MCT1 inhibitor that accumulates to high concentrations in 4T1 xenograft tumors, where it increases tumor lactate concentrations and produces beneficial effects on markers of TNBC [Read the Full Post]

In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model

526 views | Jun 25 2020

Xiaowen Guan et al. indicated AZD3965 was a potent MCT1 inhibitor that accumulated to high concentrations in 4T1 xenograft tumors, where it increased tumor lactate concentrations and produced beneficial effects on markers of TNBC [Read the Full Post]